Trial of Trastuzumab Deruxtecan in Previously Treated HER2 — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Trial of Trastuzumab Deruxtecan in Previously Treated HER2 — Stella

Recruiting

Back to Breast Cancer Metastatic trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Yale University, New Haven, Connecticut

University of Rochester Medical Center, Rochester, New York

Key details

Phase

Safety & dosing

Sponsor

Yale University

Collaborators

Daiichi Sankyo, AstraZeneca

Enrollment target

~40 participants

Started

June 2025

Primary completion

December 2028

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov